Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
NBQX is an antagonist of AMPA and kainate receptors (IC50s = 0.15 and 4.8 µM, respectively).1 It is selective for these receptors over NMDA receptors (IC50 = ≥90 µM). In vivo, NBQX (20 mg/kg) increases the latency to seizures, decreases the duration of seizures, and reduces seizure severity in a rat model of epilepsy induced by pentylenetetrazole (PTZ; Item No. 18682).2 It also suppresses relapse phase nicotine self-administration in rats.3
WARNING This product is not for human or veterinary use.
1. 2,3-
2. AMPA receptor antagonist NBQX decreased seizures by normalization of perineuronal nets. PLoS One 11(11), e0166672 (2016).
3. NBQX attenuates relapse of nicotine seeking but not nicotine and methamphetamine self-